# Beyond Blood Pressure: Salt Sensitivity as a Cardiorenal Phenotype—A Narrative Review

**Authors:** Maria Bachlitzanaki, Georgios Aletras, Eirini Bachlitzanaki, Nektaria Vasilaki, Charalampos Lydakis, Ioannis Petrakis, Emmanuel Foukarakis, Kostas Stylianou

PMC · DOI: 10.3390/life16020247 · Life · 2026-02-02

## TL;DR

This review explains how salt sensitivity affects blood pressure and kidney-heart health, emphasizing the need for personalized treatment strategies.

## Contribution

The paper synthesizes current evidence on salt-sensitive blood pressure's pathophysiology and proposes phenotype-guided therapeutic strategies.

## Key findings

- Salt sensitivity involves impaired renal sodium excretion and neurohormonal activation leading to cardiorenal dysfunction.
- Phenotype-guided therapies like RAAS blockade and SGLT2 inhibitors may improve outcomes in salt-sensitive individuals.
- Dynamic BP monitoring and targeted lab tests help identify salt-sensitive phenotypes for individualized care.

## Abstract

Background: Salt-sensitive blood pressure (SSBP) represents a prevalent yet underrecognized hypertensive phenotype, in which blood pressure (BP) and volume status are disproportionately influenced by dietary sodium intake. Beyond BP elevation alone, salt sensitivity reflects a convergence of renal sodium handling abnormalities, neurohormonal activation, vascular dysfunction, and inflammatory pathways that link excessive sodium exposure to progressive kidney injury and adverse cardiac remodeling. Given its association with chronic kidney disease (CKD) and the association of heart failure with preserved ejection fraction (HFpEF), improved recognition of SSBP has direct clinical relevance. Objective: This narrative review aims to synthesize current mechanistic and clinical evidence on SSBP, focusing on pathophysiology, cardiorenal interactions, diagnostic challenges, and phenotype-guided therapeutic strategies with practical applicability. Methods: A narrative literature review was conducted using PubMed, Scopus, and Web of Science from inception through January 2026. Experimental, translational, and clinical studies, along with relevant guideline documents, were integrated to provide conceptual and clinical interpretation rather than quantitative analysis. Key Findings: Impaired renal sodium excretion, intrarenal RAAS activation, sympathetic overactivity, endothelial dysfunction, and immune-mediated inflammation contribute to sodium retention, microvascular dysfunction, and fibrotic remodeling across the kidney–heart axis. These pathways are strongly supported by experimental and translational data, but direct interventional clinical validation remains limited for several mechanisms. Clinically, salt-sensitive individuals often exhibit non-dipping BP patterns, albuminuria, salt-induced edema, and a predisposition to HFpEF. Dynamic BP monitoring combined with targeted laboratory assessment improves identification of this phenotype and supports individualized management. Conclusions: Early recognition of SSBP enables targeted interventions beyond uniform sodium restriction. Phenotype-guided strategies integrating lifestyle modification, RAAS blockade, thiazide-like diuretics, mineralocorticoid receptor antagonists, and sodium-glucose co-transporters 2 inhibitors (SGLT2i) may improve cardiorenal outcomes. Emerging precision tools (e.g., wearable blood-pressure sensors, digital sodium tracking technologies, etc.) remain exploratory but may further refine individualized management.

## Linked entities

- **Diseases:** chronic kidney disease (MONDO:0005300)

## Full-text entities

- **Genes:** ST2 (suppression of tumorigenicity 2) [NCBI Gene 6761], RAC1 (Rac family small GTPase 1) [NCBI Gene 5879] {aka MIG5, MRD48, Rac-1, TC-25, p21-Rac1}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, SLC4A5 (solute carrier family 4 member 5) [NCBI Gene 57835] {aka NBC4, NBCe2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CEBPA (CCAAT enhancer binding protein alpha) [NCBI Gene 1050] {aka C/EBP-alpha, CEBP}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, HSD11B2 (hydroxysteroid 11-beta dehydrogenase 2) [NCBI Gene 3291] {aka AME, AME1, HSD11K, HSD2, SDR9C3}, LCN2 (lipocalin 2) [NCBI Gene 3934] {aka 24p3, MSFI, NGAL, p25}, SSBP1 (single stranded DNA binding protein 1) [NCBI Gene 6742] {aka Mt-SSB, OPA13, SOSS-B1, SSBP, mtSSB}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, CST3 (cystatin C) [NCBI Gene 1471] {aka ADLDWA, ARMD11, HEL-S-2}, MIR505 (microRNA 505) [NCBI Gene 574508] {aka MIRN505, hsa-mir-505, mir-505}, OSR1 (odd-skipped related transcription factor 1) [NCBI Gene 130497] {aka ODD}, LGALS3 (galectin 3) [NCBI Gene 3958] {aka CBP35, GAL3, GALBP, GALIG, L31, LGALS2}, ACE (angiotensin I converting enzyme) [NCBI Gene 1636] {aka ACE1, CD143, DCP, DCP1}, CUL3 (cullin 3) [NCBI Gene 8452] {aka CUL-3, NEDAUS, PHA2E}, EDN1 (endothelin 1) [NCBI Gene 1906] {aka ARCND3, ET1, HDLCQ7, PPET1, QME}, HAVCR1 (hepatitis A virus cellular receptor 1) [NCBI Gene 26762] {aka CD365, HAVCR, HAVCR-1, KIM-1, KIM1, TIM}, MIR1825 (microRNA 1825) [NCBI Gene 100302183] {aka MIRN1825, hsa-mir-1825}, STK39 (serine/threonine kinase 39) [NCBI Gene 27347] {aka DCHT, SPAK}, POSTN (periostin) [NCBI Gene 10631] {aka OSF-2, OSF2, PDLPOSTN, PN}, GIP (gastric inhibitory polypeptide) [NCBI Gene 2695], REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, MIR1263 (microRNA 1263) [NCBI Gene 100302148] {aka MIRN1263, hsa-mir-1263}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, CYP11B1 (cytochrome P450 family 11 subfamily B member 1) [NCBI Gene 1584] {aka CPN1, CYP11B, FHI, P450C11}, WNK1 (WNK lysine deficient protein kinase 1) [NCBI Gene 65125] {aka HSAN2, HSN2, KDP, PPP1R167, PRKWNK1, PSK}, SLC12A3 (solute carrier family 12 member 3) [NCBI Gene 6559] {aka NCC, NCCT, TSC}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, TTN (titin) [NCBI Gene 7273] {aka CMD1G, CMH9, CMPD4, CMYO5, CMYP5, EOMFC}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, PRKG1 (protein kinase cGMP-dependent 1) [NCBI Gene 5592] {aka AAT8, PKG, PKG1, PRKG1B, PRKGR1B, cGK}, VEGFC (vascular endothelial growth factor C) [NCBI Gene 7424] {aka Flt4-L, LMPH1D, LMPHM4, VRP}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, CYP11B2 (cytochrome P450 family 11 subfamily B member 2) [NCBI Gene 1585] {aka ALDOS, CPN2, CYP11B, CYP11BL, CYPXIB2, P-450C18}, SLC5A2 (solute carrier family 5 member 2) [NCBI Gene 6524] {aka SGLT2}, MRAS (muscle RAS oncogene homolog) [NCBI Gene 22808] {aka M-RAs, NS11, R-RAS3, RRAS3}, KLHL3 (kelch like family member 3) [NCBI Gene 26249] {aka PHA2D}, AGTR1 (angiotensin II receptor type 1) [NCBI Gene 185] {aka AG2S, AGTR1B, AT1, AT1AR, AT1B, AT1BR}, SCNN1G (sodium channel epithelial 1 subunit gamma) [NCBI Gene 6340] {aka BESC3, ENaCg, ENaCgamma, LDLS2, PHA1, PHA1B3}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, STK24 (serine/threonine kinase 24) [NCBI Gene 8428] {aka HEL-S-95, MST3, MST3B, STE20, STK3}, FOXO1 (forkhead box O1) [NCBI Gene 2308] {aka FKH1, FKHR, FOXO1A}, AGT (angiotensinogen) [NCBI Gene 183] {aka ANHU, SERPINA8, hFLT1}, CD14 (CD14 molecule) [NCBI Gene 929], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, NR3C2 (nuclear receptor subfamily 3 group C member 2) [NCBI Gene 4306] {aka MCR, MLR, MR, NR3C2VIT}, SGK1 (serum/glucocorticoid regulated kinase 1) [NCBI Gene 6446] {aka SGK}, EDNRA (endothelin receptor type A) [NCBI Gene 1909] {aka ET-A, ETA, ETA-R, ETAR, ETRA, MFDA}, NFAT5 (nuclear factor of activated T cells 5) [NCBI Gene 10725] {aka NF-AT5, NFATL1, NFATZ, OREBP, TONEBP}, AP2B1 (adaptor related protein complex 2 subunit beta 1) [NCBI Gene 163] {aka ADTB2, AP105B, AP2-BETA, CLAPB1}, VN1R17P (vomeronasal 1 receptor 17 pseudogene) [NCBI Gene 441931] {aka GPCR}, WNK4 (WNK lysine deficient protein kinase 4) [NCBI Gene 65266] {aka PHA2B, PRKWNK4}, POMC (proopiomelanocortin) [NCBI Gene 5443] {aka ACTH, CLIP, LPH, MSH, NPP, OBAIRH}, LY96 (lymphocyte antigen 96) [NCBI Gene 23643] {aka ESOP-1, MD-2, MD2, ly-96}, SCNN1B (sodium channel epithelial 1 subunit beta) [NCBI Gene 6338] {aka BESC1, ENaCb, ENaCbeta, LIDLS1, PHA1B2, SCNEB}
- **Diseases:** injury to (MESH:D014947), Inflammatory (MESH:D007249), volume overload (MESH:D019190), cardiac fibrosis (MESH:D005355), Metabolic disturbances (MESH:D024821), Liddle's syndrome (MESH:D056929), hyperkalemia (MESH:D006947), pseudohypoaldosteronism type II (MESH:D011546), myocardial remodeling (MESH:D064752), dyslipidemia (MESH:D050171), impaired natriuresis (MESH:D060825), dyspnea (MESH:D004417), diabetes mellitus (MESH:D003920), Endothelial dysfunction (MESH:D014652), dysbiosis (MESH:D064806), edema (MESH:D004487), CKD (MESH:D051436), electrolyte (MESH:D014883), hyponatremia (MESH:D007010), diastolic dysfunction (MESH:D018487), tubulointerstitial (MESH:D009395), weight gain (MESH:D015430), organ dysfunction (MESH:D009102), autoimmune (MESH:D001327), essential hypertension (MESH:D000075222), Obesity (MESH:D009765), acute kidney injury (MESH:D058186), familial hyperkalemic hypertension (OMIM:614495), metabolic (MESH:D008659), metabolic alkalosis (MESH:D000471), Gordon's syndrome (OMIM:114300), sympathetic hyperactivity (MESH:D006948), ejection (MESH:D054160), hypoxia (MESH:D000860), frailty (MESH:D000073496), cardiorenal disorders (MESH:D059347), cardio-renal injury (MESH:D044542), microvascular dysfunction (MESH:D017566), albuminuria (MESH:D000419), Hypertension (MESH:D006973), LVH (MESH:D017379), ventricular stiffness (MESH:C566112), renal and vascular injury (MESH:D020214), hyperinsulinemia (MESH:D006946), sodium retention (MESH:D016055), atherosclerosis (MESH:D050197), myocardial and vascular remodeling (MESH:D066253), congestion (MESH:D002311), cardiovascular and renal disease (MESH:D002318), impaired sodium (MESH:C562576), vascular dysfunction (MESH:D002561), endothelial injury (MESH:D057772), Weight loss (MESH:D015431), impaired diastolic relaxation (MESH:D006337), insulin resistance (MESH:D007333), type 2 diabetes (MESH:D003924), obstructive sleep apnea (MESH:D020181), collagen (MESH:D003095), HF (MESH:D006333), organ damage (MESH:D000092124)
- **Chemicals:** Sodium chloride (MESH:D012965), sugars (MESH:D000073893), chlorthalidone (MESH:D002752), Salt (MESH:D012492), urate (MESH:D014527), prostaglandins (MESH:D011453), aldosterone (MESH:D000450), water (MESH:D014867), IsoLG (MESH:C000629758), eplerenone (MESH:D000077545), dietary sodium (MESH:D012982), norepinephrine (MESH:D009638), NO (MESH:D009569), Thiazide (MESH:D049971), chloride (MESH:D002712), SGLT2i (-), K+ (MESH:D011188), Na+ (MESH:D012964), catecholamines (MESH:D002395), Cl- (MESH:D002713), lipid (MESH:D008055), indapamide (MESH:D007190), alcohol (MESH:D000438), glucose (MESH:D005947), creatinine (MESH:D003404), ROS (MESH:D017382), finerenone (MESH:C576501)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], gut metagenome (species) [taxon 749906]
- **Mutations:** -572C/G, T174M, M235T, -308G/A

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12942530/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942530/full.md

## References

134 references — full list in the complete paper: https://tomesphere.com/paper/PMC12942530/full.md

---
Source: https://tomesphere.com/paper/PMC12942530